quinoxalines has been researched along with Angiogenesis, Pathologic in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abulafia, W; Bentzien, F; Buhr, CA; Chen, J; Chu, F; Dale, S; Du, X; Foster, P; Hsu, PP; Jaeger, CT; Laird, AD; Lam, ST; Lamb, P; Lee, M; Matthews, DJ; Plonowski, A; Qian, F; Shen, P; Won, KA; Wu, J; Yakes, FM; Yamaguchi, K; Young, J; Yu, P; Zhang, W | 1 |
| Abulafia, W; Bentzien, F; Chen, J; Chu, F; Dale, S; Du, X; Engell, K; Foster, P; Hsu, PP; Jaeger, CT; Keast, P; Laird, AD; Lam, ST; Lamb, P; Marlowe, CK; Matthews, DJ; Plonowski, A; Qian, F; Won, KA; Wu, J; Yakes, FM; Yamaguchi, K; Young, J; Yturralde, O; Yu, P; Zhang, W | 1 |
| Barraja, P; Beall, HD; Bunderson, M; Moody, CJ; Newsome, JJ; Swann, E; Tooke, JE; Whatmore, JL | 1 |
| Chao, J; Hsieh, CM; Kawasaki, K; Liao, JK; Smith, RS; Sun, J | 1 |
| Al-Hmaira, J; Gali-Muhtasib, H; Geara, F; Haddadin, MJ; Mona, AD; Sidani, M; Zaatari, G | 1 |
| Baker, CH; Caron, A; Fidler, IJ; Gallick, GE; Nesbit, M; Summy, JM; Trevino, JG; Zhang, F | 1 |
| Cambria, RA; Gloviczki, P; Lowell, RC; Miller, VM | 1 |
7 other study(ies) available for quinoxalines and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Disease Models, Animal; Humans; Inhibitory Concentration 50; Mice; Neoplasms; Neovascularization, Pathologic; Phosphatidylinositol Phosphates; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Ribosomal Protein S6 Kinases; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinoxalines; Ribosomal Protein S6 Kinases; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Comparative study of isoflavone, quinoxaline and oxindole families of anti-angiogenic agents.
Topics: Angiogenesis Inhibitors; Endothelium, Vascular; Humans; Indoles; Isoflavones; Neoplasms; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Quinoxalines | 2002 |
Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis.
Topics: Adenoviridae; Animals; Blotting, Western; Capillaries; Cell Adhesion; Cell Division; Cell Movement; Cells, Cultured; Cyclic GMP-Dependent Protein Kinases; DNA, Complementary; Dose-Response Relationship, Drug; Endothelium; Endothelium, Vascular; Enzyme Inhibitors; Gene Transfer Techniques; Humans; Ischemia; Laser-Doppler Flowmetry; Neovascularization, Pathologic; Nitric Oxide; Nitric Oxide Synthase; Nitroso Compounds; Oxadiazoles; Phosphatidylinositol 3-Kinases; Phosphorylation; Precipitin Tests; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinoxalines; Rats; Recombinant Proteins; S-Nitrosoglutathione; Time Factors | 2003 |
Quinoxaline 1,4-dioxides are novel angiogenesis inhibitors that potentiate antitumor effects of ionizing radiation.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Blotting, Western; Carcinoma, Lewis Lung; Cell Hypoxia; Cell Survival; Collagen; Combined Modality Therapy; Drug Combinations; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Laminin; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Necrosis; Neovascularization, Pathologic; Proteoglycans; Quinoxalines; Radiation Tolerance; Radiation-Sensitizing Agents; Radiation, Ionizing; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor A | 2004 |
Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; src-Family Kinases | 2006 |
Chronic changes in blood flow alter endothelium-dependent responses in autogenous vein grafts in dogs.
Topics: Acetylcholine; Adenosine Diphosphate; Adrenergic alpha-Agonists; Animals; Arginine; Arteriovenous Shunt, Surgical; Blood Flow Velocity; Brimonidine Tartrate; Calcimycin; Constriction; Dinoprost; Dogs; Endothelins; Endothelium, Vascular; Femoral Artery; Femoral Vein; Hyperplasia; Male; Models, Biological; Neovascularization, Pathologic; Nitric Oxide; omega-N-Methylarginine; Quinoxalines; Thrombin; Tunica Intima; Vascular Patency | 1994 |